Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes

AimTo assess oxytocin's acute glucoregulatory impact in men with type 2 diabetes in the context of our previous findings that oxytocin improves beta-cell responsivity in healthy men.MethodsIn a double-blind, crossover comparison, intranasal oxytocin (24 IU) and placebo, respectively, were administered to 25 fasted men with non-insulin-treated type 2 diabetes (age +/- standard error of the mean, 63.40 +/- 1.36 years; body mass index, 27.77 +/- 0.66 kg/m2; HbA1c, 6.86% +/- 0.08%; Homeostatic Model Assessment of Insulin Resistance (HOMA-IR, 3.44 +/- 0.39) 60 minutes before an oral glucose tolerance test (oGTT). Key outcomes were compared with previous results in men with normal weight or obesity.ResultsOxytocin compared with placebo increased plasma oxytocin concentrations and reduced the heart rate, but did not alter glucose metabolism in the 3 hours after oGTT onset (area under the curve, glucose, 2240 +/- 80.5 vs. 2190 +/- 69.5 mmol/L x min; insulin, 45 663 +/- 4538 vs. 44 343 +/- 4269 pmol/L x min; C-peptide, 235 +/- 5.1 vs. 231 +/- 15.9 nmol/L x min).ConclusionsThis outcome contrasts with the oxytocin-induced attenuation of early postprandial glucose excursions in normal-weight individuals, but is in line with the absence of respective effects in men with obesity. We conclude that insulin resistance in type 2 diabetes is associated with decreased sensitivity to the acute glucoregulatory effect of oxytocin in male individuals.